By Jaime Llinares Taboada

 

GlaxoSmithKline PLC said Tuesday that new preclinical studies demonstrated that its sotrovimab antibody retains activity against the Omicron coronavirus variant.

The British pharmaceutical major said sotrovimab retains in vitro activity against the full known Omicron spike protein.

These findings build on initial preclinical data provided last week, showing that the antibody retains activity against all tested variants of concern.

"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO [World Health Organization], and we look forward to discussing these results with regulatory authorities around the world," Chief Scientific Officer Hal Barron said.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

December 07, 2021 02:36 ET (07:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.